サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1578300

心房細動治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2024年～2032年）

Global Atrial Fibrillation Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
心房細動治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、予測（2024年～2032年）
出版日: 2024年09月01日
発行: Value Market Research
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の心房細動治療薬の市場規模は、2023年の221億3,000万米ドルから、2032年には302億6,000万米ドル近くに達し、調査期間2024年～2032年のCAGRは3.54%と推定されます。

一般にAFibとして知られる心房細動は、心臓の上室の急速で不規則な拍動が読み取られる心臓の異常状態を指します。心房細動治療薬は、心拍数を調節して血栓を防ぐことにより、心房細動の治療と管理に使用されます。心房細動は、血液が心房から心室へ正常に流れるのを妨げます。心房細動治療薬は、心臓の上室と下室が協力して血液をうまく送り出すのを助けます。また、心房細動治療薬は、血栓を予防し、心臓のリズムをリセットし、脳卒中の可能性を低下させ、心拍数をコントロールします。

市場力学

世界の高齢者人口の増加、肥満、慢性疾患の高い有病率、虚血性心疾患は心房細動の高リスク因子です。これらの要因が心房細動治療薬市場を活性化すると予想されます。また、世界のアルコール消費量の着実な増加も市場の成長を促進する可能性があります。しかし、抗凝固薬の高価格とAfib治療薬の使用に伴う副作用は、世界市場を抑制する可能性があります。また、SARS-CoV-2ウイルスによるパンデミックは低酸素症を引き起こし、特に高齢の感染者に心房細動をもたらす可能性があります。この要因は、心房細動治療薬メーカーに有利なビジネス展望をもたらすと予測されています。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは心房細動治療薬の世界市場における各セグメントを包括的に評価することもできます。心房細動治療薬産業の成長と動向は、この調査に全体的なアプローチを提供します。

市場セグメンテーション

心房細動治療薬市場レポートのこのセクションでは、国および地域レベルのセグメントに関する詳細なデータを提供することで、戦略担当者がそれぞれの製品またはサービスのターゲット層を特定し、今後のビジネスチャンスに役立てることができます。

地域別分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカの地域展望をカバーし、市場の現在と将来の需要を明らかにしています。さらに、すべての主要地域における個々の用途セグメントの需要・推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 心房細動治療薬- 産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 心房細動治療薬の世界市場分析：製品別

  • 概要：製品別
  • 実績・予測データ分析：製品別
  • 抗不整脈薬
  • 抗凝固薬（ビタミンK拮抗薬（VKA）、新規経口抗凝固薬（NOAC）、直接トロンビン阻害薬、直接第Xa因子阻害薬）

第6章 心房細動治療薬の世界市場分析：心房細動タイプ別

  • 概要：心房細動タイプ別
  • 実績・予測データ分析：心房細動タイプ別
  • 発作性
  • 持続性
  • 永続性

第7章 心房細動治療薬の世界市場分析：用途別

  • 概要：用途別
  • 実績・予測データ分析：用途別
  • 心拍リズムコントロール
  • 心拍コントロール

第8章 心房細動治療薬の世界市場分析：投与経路別

  • 概要：投与経路別
  • 実績・予測データ分析：投与経路別
  • 経口剤
  • 注射剤

第9章 心房細動治療薬の世界市場分析：最終用途別

  • 概要：最終用途別
  • 実績・予測データ分析：最終用途別
  • 病院
  • 心臓センター
  • 外来手術センター
  • その他

第10章 心房細動治療薬の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米の売上分析
    • 概要・実績・予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州の売上分析
    • 概要・実績・予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋の売上分析
    • 概要・実績・予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋
  • ラテンアメリカの売上分析
    • 概要・実績・予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカの売上分析
    • 概要・実績・予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東・アフリカ

第11章 心房細動治療薬企業の競合情勢

  • 心房細動治療薬市場の競合
  • パートナーシップ/提携/協定
  • 合併・買収
  • 新製品発売
  • その他の開発

第12章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Johnson & Johnson
  • Pfizer
  • Sanofi
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • AstraZeneca
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Product (USD MN)
  • Antiarrhythmic Drugs Market Sales By Geography (USD MN)
  • Anticoagulant Drugs (Vitamin K Antagonists (VKA), Novel Oral Anticoagulants (NOACs) (Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors)) Market Sales By Geography (USD MN)
  • Analysis By Atrial Fibrillation Type (USD MN)
  • Paroxysmal Market Sales By Geography (USD MN)
  • Persistent Market Sales By Geography (USD MN)
  • Permanent Market Sales By Geography (USD MN)
  • Analysis By Application (USD MN)
  • Heart Rhythm Control Market Sales By Geography (USD MN)
  • Heart Rate Control Market Sales By Geography (USD MN)
  • Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Injectable Market Sales By Geography (USD MN)
  • Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Cardiac Centers Market Sales By Geography (USD MN)
  • Ambulatory Surgical Centers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Atrial Fibrillation Drugs Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Atrial Fibrillation Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global Atrial Fibrillation Drugs Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Product
  • Market Attractiveness Analysis By Atrial Fibrillation Type
  • Market Attractiveness Analysis By Application
  • Market Attractiveness Analysis By Route of Administration
  • Market Attractiveness Analysis By End-use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Product (USD MN)
  • Antiarrhythmic Drugs Market Sales By Geography (USD MN)
  • Anticoagulant Drugs (Vitamin K Antagonists (VKA), Novel Oral Anticoagulants (NOACs) (Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors)) Market Sales By Geography (USD MN)
  • Global Market Analysis By Atrial Fibrillation Type (USD MN)
  • Paroxysmal Market Sales By Geography (USD MN)
  • Persistent Market Sales By Geography (USD MN)
  • Permanent Market Sales By Geography (USD MN)
  • Global Market Analysis By Application (USD MN)
  • Heart Rhythm Control Market Sales By Geography (USD MN)
  • Heart Rate Control Market Sales By Geography (USD MN)
  • Global Market Analysis By Route of Administration (USD MN)
  • Oral Market Sales By Geography (USD MN)
  • Injectable Market Sales By Geography (USD MN)
  • Global Market Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Cardiac Centers Market Sales By Geography (USD MN)
  • Ambulatory Surgical Centers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11212128

The global demand for Atrial Fibrillation Drugs Market is presumed to reach the market size of nearly USD 30.26 Billion by 2032 from USD 22.13 Billion in 2023 with a CAGR of 3.54% under the study period 2024-2032.

Atrial fibrillation, commonly known as AFib refers to an abnormal heart condition interpreted by the rapid and irregular beating of the upper chambers of the heart. Atrial fibrillation drugs or medicines are used for the treatment and management of AFib conditions by regulating heart rate to prevent blood clots. AFib condition prevents blood from flowing normally from atria to the ventricles. The AFib medicines help the heart's upper and lower chambers to work together to pump blood better. The atrial fibrillation drugs work by preventing blood clots, resets heart rhythm, lower the chances of a stroke, and control the heart rate.

MARKET DYNAMICS

The global rise in the elderly population, obesity, high prevalence of chronic diseases, and ischemic heart diseases pose high-risk factors for AFib condition. These factors are anticipated to fuel atrial fibrillation drug markets. Also, the steady growth of global alcohol consumption may drive market growth. However, the high cost of anticoagulants and adverse effects associated with the consumption of Afib drugs exhibit the potential to restrain the global market. The pandemic caused by the SARS-CoV-2 virus is causing hypoxia, which may bring about atrial fibrillation in the infected patients specifically elderly. This factor is foreseen to create lucrative business prospects for AFib drug manufacturers.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Atrial Fibrillation Drugs. The growth and trends of Atrial Fibrillation Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Atrial Fibrillation Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

  • Antiarrhythmic Drugs
  • Anticoagulant Drugs (Vitamin K Antagonists (VKA), Novel Oral Anticoagulants (NOACs) (Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors))

By Atrial Fibrillation Type

  • Paroxysmal
  • Persistent
  • Permanent

By Application

  • Heart Rhythm Control
  • Heart Rate Control

By Route of Administration

  • Oral
  • Injectable

By End-use

  • Hospitals
  • Cardiac Centers
  • Ambulatory Surgical Centers
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Atrial Fibrillation Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Atrial Fibrillation Drugs market include Johnson & Johnson, Pfizer, Sanofi, Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, AstraZeneca. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. ATRIAL FIBRILLATION DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Product
    • 3.7.2 Market Attractiveness Analysis By Atrial Fibrillation Type
    • 3.7.3 Market Attractiveness Analysis By Application
    • 3.7.4 Market Attractiveness Analysis By Route of Administration
    • 3.7.5 Market Attractiveness Analysis By End-use
    • 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ATRIAL FIBRILLATION DRUGS MARKET ANALYSIS BY PRODUCT

  • 5.1. Overview By Product
  • 5.2. Historical and Forecast Data Analysis By Product
  • 5.3. Antiarrhythmic Drugs Historic and Forecast Sales By Regions
  • 5.4. Anticoagulant Drugs (Vitamin K Antagonists (VKA), Novel Oral Anticoagulants (NOACs) (Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors)) Historic and Forecast Sales By Regions

6. GLOBAL ATRIAL FIBRILLATION DRUGS MARKET ANALYSIS BY ATRIAL FIBRILLATION TYPE

  • 6.1. Overview By Atrial Fibrillation Type
  • 6.2. Historical and Forecast Data Analysis By Atrial Fibrillation Type
  • 6.3. Paroxysmal Historic and Forecast Sales By Regions
  • 6.4. Persistent Historic and Forecast Sales By Regions
  • 6.5. Permanent Historic and Forecast Sales By Regions

7. GLOBAL ATRIAL FIBRILLATION DRUGS MARKET ANALYSIS BY APPLICATION

  • 7.1. Overview By Application
  • 7.2. Historical and Forecast Data Analysis By Application
  • 7.3. Heart Rhythm Control Historic and Forecast Sales By Regions
  • 7.4. Heart Rate Control Historic and Forecast Sales By Regions

8. GLOBAL ATRIAL FIBRILLATION DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

  • 8.1. Overview By Route of Administration
  • 8.2. Historical and Forecast Data Analysis By Route of Administration
  • 8.3. Oral Historic and Forecast Sales By Regions
  • 8.4. Injectable Historic and Forecast Sales By Regions

9. GLOBAL ATRIAL FIBRILLATION DRUGS MARKET ANALYSIS BY END-USE

  • 9.1. Overview By End-use
  • 9.2. Historical and Forecast Data Analysis By End-use
  • 9.3. Hospitals Historic and Forecast Sales By Regions
  • 9.4. Cardiac Centers Historic and Forecast Sales By Regions
  • 9.5. Ambulatory Surgical Centers Historic and Forecast Sales By Regions
  • 9.6. Others Historic and Forecast Sales By Regions

10. GLOBAL ATRIAL FIBRILLATION DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 10.1. Regional Outlook
  • 10.2. Introduction
  • 10.3. North America Sales Analysis
    • 10.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.3.2 North America By Segment Sales Analysis
    • 10.3.3 North America By Country Sales Analysis
    • 10.3.4 United States Sales Analysis
    • 10.3.5 Canada Sales Analysis
    • 10.3.6 Mexico Sales Analysis
  • 10.4. Europe Sales Analysis
    • 10.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.4.2 Europe By Segment Sales Analysis
    • 10.4.3 Europe By Country Sales Analysis
    • 10.4.4 United Kingdom Sales Analysis
    • 10.4.5 France Sales Analysis
    • 10.4.6 Germany Sales Analysis
    • 10.4.7 Italy Sales Analysis
    • 10.4.8 Russia Sales Analysis
    • 10.4.9 Rest Of Europe Sales Analysis
  • 10.5. Asia Pacific Sales Analysis
    • 10.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.5.2 Asia Pacific By Segment Sales Analysis
    • 10.5.3 Asia Pacific By Country Sales Analysis
    • 10.5.4 China Sales Analysis
    • 10.5.5 India Sales Analysis
    • 10.5.6 Japan Sales Analysis
    • 10.5.7 South Korea Sales Analysis
    • 10.5.8 Australia Sales Analysis
    • 10.5.9 South East Asia Sales Analysis
    • 10.5.10 Rest Of Asia Pacific Sales Analysis
  • 10.6. Latin America Sales Analysis
    • 10.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.6.2 Latin America By Segment Sales Analysis
    • 10.6.3 Latin America By Country Sales Analysis
    • 10.6.4 Brazil Sales Analysis
    • 10.6.5 Argentina Sales Analysis
    • 10.6.6 Peru Sales Analysis
    • 10.6.7 Chile Sales Analysis
    • 10.6.8 Rest of Latin America Sales Analysis
  • 10.7. Middle East & Africa Sales Analysis
    • 10.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 10.7.2 Middle East & Africa By Segment Sales Analysis
    • 10.7.3 Middle East & Africa By Country Sales Analysis
    • 10.7.4 Saudi Arabia Sales Analysis
    • 10.7.5 UAE Sales Analysis
    • 10.7.6 Israel Sales Analysis
    • 10.7.7 South Africa Sales Analysis
    • 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE ATRIAL FIBRILLATION DRUGS COMPANIES

  • 11.1. Atrial Fibrillation Drugs Market Competition
  • 11.2. Partnership/Collaboration/Agreement
  • 11.3. Merger And Acquisitions
  • 11.4. New Product Launch
  • 11.5. Other Developments

12. COMPANY PROFILES OF ATRIAL FIBRILLATION DRUGS INDUSTRY

  • 12.1. Top Companies Market Share Analysis
  • 12.2. Market Concentration Rate
  • 12.3. Johnson & Johnson
    • 12.3.1 Company Overview
    • 12.3.2 Company Revenue
    • 12.3.3 Products
    • 12.3.4 Recent Developments
  • 12.4. Pfizer
    • 12.4.1 Company Overview
    • 12.4.2 Company Revenue
    • 12.4.3 Products
    • 12.4.4 Recent Developments
  • 12.5. Sanofi
    • 12.5.1 Company Overview
    • 12.5.2 Company Revenue
    • 12.5.3 Products
    • 12.5.4 Recent Developments
  • 12.6. Bayer AG
    • 12.6.1 Company Overview
    • 12.6.2 Company Revenue
    • 12.6.3 Products
    • 12.6.4 Recent Developments
  • 12.7. Boehringer Ingelheim
    • 12.7.1 Company Overview
    • 12.7.2 Company Revenue
    • 12.7.3 Products
    • 12.7.4 Recent Developments
  • 12.8. Bristol-Myers Squibb
    • 12.8.1 Company Overview
    • 12.8.2 Company Revenue
    • 12.8.3 Products
    • 12.8.4 Recent Developments
  • 12.9. Daiichi Sankyo
    • 12.9.1 Company Overview
    • 12.9.2 Company Revenue
    • 12.9.3 Products
    • 12.9.4 Recent Developments
  • 12.10. AstraZeneca
    • 12.10.1 Company Overview
    • 12.10.2 Company Revenue
    • 12.10.3 Products
    • 12.10.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies